Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for Confidential Treatment under Rule 406 under the Securities Act of 1933, as amended. Confidential Portions are marked: [***] ASSET...Asset Purchase Agreement • November 10th, 2014 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
This ASSET PURCHASE AGREEMENT (this “Agreement”) is entered into as of July 1, 2014 (the “Closing Date”), by and between Noven Therapeutics, LLC, a Delaware limited liability company formerly known as JDS Pharmaceuticals, LLC (the “Seller”) and ANI Pharmaceuticals, Inc., a Delaware corporation (the “Buyer”). The Seller and the Buyer are referred to hereinafter individually as a “Party” and collectively as the “Parties.”
ASSET PURCHASE AGREEMENT dated as of August 1, 2014 among ANI PHARMACEUTICALS, INC. and SHIRE VIROPHARMA INCORPORATED Confidential Materials Omitted and Filed Separately with the Securities and Exchange Commission Pursuant to a Request for...Asset Purchase Agreement • November 10th, 2014 • Ani Pharmaceuticals Inc • Pharmaceutical preparations • New York
ASSET PURCHASE AGREEMENT (this “Agreement”) dated as of August 1, 2014 between ANI Pharmaceuticals, Inc., a Delaware corporation (“Buyer”), and Shire ViroPharma Incorporated, a Delaware corporation (the “Seller”).
